Clinical Trial Update: An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating pafolacianine as an imaging agent to identify lesions in pediatric patients with primary or metastatic solid tumors; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abdominal Neoplasms
• Malignant Solid Neoplasms
• Malignant Solid Tumors
• Neck Neoplasms
• Pelvic Neoplasms
• Thoracic Neoplasms

Drugs mentioned

• Pafolacianine (pafolacianine)

Snippet

Sponsor: Mayo Clinic | Conditions: Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm | Phase 3 | Status: RECRUITING